Clinical trial · Interventional
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
The Efficacy and Safety of Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Allogeneic stem cell transplantation (Allo-HSCT) is the effective and even the only treatment option for acute leukemia. The haplo-hematopoietic stem cell transplantation(haplo-HSCT) and "GIAC" protocol have crossed HLA barrier and helped more patients find donors. However, the engraftment failure and incidence of graft-versus-host disease(GVHD) limit the prognosis of patients who receive the haplo-HSCT. It is believed that Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation improved hematopoietic reconstitution and reduced the incidence of GVHD, there is still no consensus about the efficacy and safety of this kind of therapy. This prospective, randomized and controlled study is to investigate the efficacy and safety of Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Leukemia | Acute Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation | Procedure | — | UNRESOLVED |
| haploidentical hematopoietic stem cell transplantation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Haplo-HSCT group
- description
- 58 patients will be involved in this group
- interventionNames
- Procedure: haploidentical hematopoietic stem cell transplantation
- type
- EXPERIMENTAL
- label
- Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation group
- description
- 58 patients will be involved in this group
- interventionNames
- Procedure: Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation
Primary outcomes (2)
- measure
- Overall survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Ages 16-65 years inclusive. * Diagnosed as acute leukemia, planning to receive haplo-HSCT * Eastern Cooperative Oncology Group (ECOG) Performance status 0-2 * Presence of an available haploidentical donor * Signing written informed consent and agreeing with taking designated umbilical cord blood Exclusion Criteria: * Uncontrolled infections less than 4 weeks prior to enrollment * Secondary malignancy * Psychiatric illness that would limit compliance with study requirements * Impairment of heart, hepatic or renal function to such an extent that the patient, in the opinion of the investigator, will be exposed to an excessive risk if entered into this clinical study * Allergic to blood products * Other causes which are not suitable for the trial in investigator's consideration
References
Publications (0)
Data not yet available